Genetic evidence for an essential role of neuronally expressed IL-6 signal transducer gp130 in the induction and maintenance of experimentally induced mechanical hypersensitivity in vivo and in vitro

Molecular Pain

Michaela Kress²  Claudia Sommer³  Nurcan Üçeyler³  Cristina E Constantin¹  Christian Vogl⁴  Serena Quarta² 

[1] Institute of Physiology, University of Freiburg, Freiburg, Germany;Div. Physiology, DPMP, Medical University Innsbruck, Innsbruck, Austria;Neurology Hospital, University Würzburg, Würzburg, Germany;School of Pharmacy, University of Reading, Reading, UK

关键词: allodynia;    hyperalgesia;    nociceptor sensitization;    chronic pain;    Interleukin-6;    proinflammatory cytokine;   

Others  :  865741
DOI  :  10.1186/1744-8069-7-73

 received in 2011-04-28, accepted in 2011-09-27,  发布年份 2011

【 摘 要 】

Tenderness and mechanical allodynia are key symptoms of malignant tumor, inflammation and neuropathy. The proinflammatory cytokine interleukin-6 (IL-6) is causally involved in all three pathologies. IL-6 not only regulates innate immunity and inflammation but also causes nociceptor sensitization and hyperalgesia. In general and in most cell types including immune cells and sensory neurons, IL-6 binds soluble μ receptor subunits which heteromerizes with membrane bound IL-6 signal transducer gp130. In the present study, we used a conditional knock-out strategy to investigate the importance of signal transducer gp130 expressed in C nociceptors for the generation and maintenance of mechanical hypersensitivity. Nociceptors were sensitized to mechanical stimuli by experimental tumor and this nociceptor sensitization was preserved at later stages of the pathology in control mice. However, in mice with a conditional deletion of gp130 in Nav1.8 expressing nociceptors mechanical hypersensitivity by experimental tumor, nerve injury or inflammation recovery was not preserved in the maintenance phase and nociceptors exhibited normal mechanical thresholds comparable to untreated mice. Together, the results argue for IL-6 signal transducer gp130 as an essential prerequisite in nociceptors for long-term mechanical hypersensitivity associated with cancer, inflammation and nerve injury.

【 授权许可】

   
2011 Quarta et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Jüttler E, Tarabin V, Schwaninger M: Interleukin-6 (IL-6): a possible neuromodulator induced by neuronal activity. Neuroscientist 2002, 8:268-275.
• [2]Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, Sato K, Shimizu M, Maini R, Feldmann M, et al.: Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988, 18:1797-1801.
• [3]Arvidson NG, Gudbjornsson B, Elfman L, Ryden AC, Totterman TH, Hallgren R: Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis 1994, 53:521-524.
• [4]Takeuchi E, Ito M, Mori M, Yamaguchi T, Nakagawa M, Yokota S, Nishikawa H, Sakuma-Mochizuki J, Hayashi S, Ogura T: Lung cancer producing interleukin-6. Intern Med 1996, 35:212-214.
• [5]Yamaguchi T, Yamamoto Y, Yokota S, Nakagawa M, Ito M, Ogura T: Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn J Clin Oncol 1998, 28:740-744.
• [6]DeLeo JA, Colburn RW, Nichols M, Malhotra A: Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res 1996, 16:695-700.
• [7]Murphy PG, Ramer MS, Borthwick L, Gauldie J, Richardson PM, Bisby MA: Endogenous interleukin-6 contributes to hypersensitivity to cutaneous stimuli and changes in neuropeptides asociated with chronic nerve constriction in mice. Eur J Neurosci 1999, 11:2243-2253.
• [8]Okamoto K, Martin DP, Schmelzer JD, Mitsui Y, Low PA: Pro- and anti-inflammatory cytokine expression in rat sciatic nerve chronic constriction injury model of neuropathic pain. Exp Neurol 2001, 169:386-391.
• [9]Oprée A, Kress M: Involvement of the proinflammatory cytokines tumor necrosis factor-μ, IL-1β and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin. J Neurosci 2000, 20:6289-6293.
• [10]Andratsch M, Mair N, Constantin CE, Scherbakov N, Benetti C, Quarta S, Vogl C, Sailer CA, Üceyler N, Brockhaus J, Martini R, Sommer C, Zeilhofer HU, Müller W, Kuner R, Davis JB, Rose-John S, Kress M: A key role for gp130 expressed on peripheral sensory nerves in pathological pain. J Neurosci 2009, 29:13473-13483.
• [11]Obreja O, Schmelz M, Poole S, Kress M: Interleukin-6 in combination with its soluble IL-6 receptor sensitises rat skin nociceptors to heat, in vivo. Pain 2002, 96:57-62.
• [12]Obreja O, Biasio W, Andratsch M, Lips KS, Rathee PK, Ludwig A, Rose-John S, Kress M: Fast modulation of heat-activated ionic current by proinflammatory interleukin 6 in rat sensory neurons. Brain 2005, 128:1634-1641.
• [13]Xu XJ, Hao JX, Andell-Jonsson S, Poli V, Bartfai T, Wiesenfeld-Hallin Z: Nociceptive responses in interleukin-6-deficient mice to peripheral inflammation and peripheral nerve section. Cytokine 1997, 9:1028-1033.
• [14]Zhong J, Dietzel DI, Wahle P, Kopf M, Heumann R: Sensory impairments and delayed regeneration of sensory axons in interleukin-6-deficient mice. J Neurosci 1999, 19:4305-4313.
• [15]Ferreira SH, Lorenzetti BB, Poole S: Bradykinin initiates cytokine-mediated inflammatory hyperalgesia. Br J Pharmacol 1993, 110:1227-1231.
• [16]Gardiner NJ, Cafferty WB, Slack SE, Thompson SW: Expression of gp130 and leukaemia inhibitory factor receptor subunits in adult rat sensory neurones: regulation by nerve injury. J Neurochem 2002, 83:100-109.
• [17]Brenn D, Richter F, Schaible HG: Sensitization of unmyelinated sensory fibers of the joint nerve to mechanical stimuli by interleukin-6 in teh rat: an inflammatory mechanism of joint pain. Arthritis Rheum 2007, 56:351-359.
• [18]Melemedjian OK, Asiedu MN, Tillu DV, Peebles KA, Yan J, Ertz N, Dussor GO, Price DJ: IL-6- and NGF-Induced Rapid Control of Protein Synthesis and Nociceptive Plasticity via Convergent Signaling to the eIF4F Complex. J Neurosci 2010, 30:15113-15123.
• [19]Fasnacht N, Müller W: Conditional gp130 deficient mouse mutants. Semin Cell Developm Biol 2008, 19:379-384.
• [20]Delaney A, Fleetwood Walker SM, Colvin LA, Fallon M: Translational medicine: cancer pain mechanisms and management. Br J Anaesth 2008, 101:97-94.
• [21]Constantin CE, Mair N, Sailer CA, Andratsch M, Xu ZZ, Blumer MJ, Scherbakov N, Davis JB, Bluethmann H, Ji RR, Kress M: Endogenous necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model. J Neurosci 2008, 28:5072-5081.
• [22]Bennett GJ: Pathophysiology and animal models of cancer-related painful peripheral neuropathy. The Oncologist 2010, 15(suppl 2):9-12.
• [23]Cunha TM, Verri WA Jr, Silva JS, Poole S, Cunha FQ, Ferreira SH: A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc Nat Acad Sci USA 2005, 102:1755-1760.
• [24]Sommer C, Kress M: Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 2004, 361:184-187.
• [25]Brown MA, Metcalf D, Gough NM: Leukemia inhibitory factor and interleukin 6 are expressed at very low levels in the normal adult mouse and are induced by inflammation. Cytokine 1994, 6:300-309.
• [26]Engert S, Wendland JR, Schwab A, Petersen M: Leukemia inhibitory factor differentially regulates capsaicin and heat sensitivity in cultured rat dorsal root ganglion neurons. Neuropeptides 2008, 42:193-197.
• [27]Thompson SW, Dray A, Urban L: Leukemia inhibitory factor induces mechanical allodynia but not thermal hyperalgesia in the juvenile rat. Neurosci 1996, 71:1091-1094.
• [28]Banner LR, Patterson PH, Allchorne A, Poole S, Woolf CJ: Leukemia infhibitor factor is an anti-inflammatory and analgesic cytokine. J Neurosci 1998, 18:5456-5462.
• [29]Tanaka M, Miyahima A: Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 2004, 149:39-52.
• [30]Morikawa Y, Tamura S, Minehata K, Donovan PJ, Mijayima A, Senba E: Essential function of oncostatin m in nociceptive neurons of dorsal root ganglia. J Neurosci 2004, 24:1941-1947.
• [31]Tamura S, Morikawa Y, Miyajima A, Senba E: Expression of oncostatin M receptor beta in a specific subset of nociceptive sensory neurons. Eur J Neurosci 2003, 17:2287-2298.
• [32]Tamura S, Morikawa Y, Senba E: Up-regulated phosphorylation of signal transducer and activator of transcription 3 and cyclic AMP-responsive element binding protein by peripheral inflammation in primary afferent neurons possibly through oncostatin M receptor. Neurosci 2005, 133:797-806.
• [33]Kiefer R, Kieseier BC, Stoll G, Hartung HP: The role of macrophages in immune-mediated damage to the peripheral nervous system. Progr Neurobiol 2001, 64:109-124.
• [34]Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET: Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001, 12:33-40.
• [35]Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH: Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology 2001, 40:743-749.
• [36]Ohzato H, Monden M, Yoshizaki K, Ogata A, Nishimoto N, Gotoh M, Kishimoto T, Mori T: Systemic production of interleukin-6 following acute inflammation. Biochem Biophys Res Comm 1993, 197:1556-1562.
• [37]Atreya R, Mudter F, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann B, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschback F, Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF: Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000, 6:583-588.
• [38]Lindenlaub T, Sommer C: Cytokines in sural biopsies from inflammatory and non-inflammatory neuropathies. Acta Neuropathol 2003, 105:593-602.
• [39]Hirota H, Kiyama H, Kishimoto T, Taga T: Accelerated nerve regeneration in mice by upregulated expression of Interleukin (IL) 6 and IL-6 receptor after trauma. J Exp Med 1996, 183:2627-2634.
• [40]Cafferty WBJ, Gardiner NJ, Das P, Qiu J, McMahon SB, Thompson SWN: Conditioning injury-induced spinal axon regeneration fails in interleukin-6 knock-out mice. J Neurosci 2004, 24:4432-4443.
• [41]Shuto T, Horie H, Hikawa N, Sango K, Tokashiki A, Murata H, Yamamoto I, Ishikawa Y: IL-6 up-regulates CNTF mRNA expression and enhances neurite regeneration. Neuroreport 2001, 21:1081-1085.
• [42]Ma W, Quirion R: Up-regulation of interleukin-6 induced by prostaglandin E2 from invading macrophages following nerve injury: an in vivo and in vitro study. J Neurochem 2005, 93:664-673.
• [43]Poole S, Cunha FQ, Selkirk S, Lorenzetti BB, Ferreira SH: Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10. Br J Pharmacol 1995, 115:684-688.
• [44]Oka T, Oka K, Hosoi M, Hori T: Intracerebroventricular injection of interleukin-6 induces thermal hyperalgesia in rats. Brain Res 1995, 692:123-128.
• [45]Vardanyan M, Melemedjian OK, Price TJ, Ossipov MH, Lai J, Roberts E, Boos TL, Deschamps JR, Jacobson AE, Rice KC, Porreca F: Reversal of pancreatitis-induced pain by an orally available, small molecule interleukin-6 receptor antagonist. Pain 2010, 115:257-265.
• [46]Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J: Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of saftey and efficacy in a 5-year extension study. Ann Rheum Dis 2009, 68:1580.
• [47]Rose-John S, Heinrich P: Soluble receptors for cytokines and growht factors: generation and biological function. Biochem J 1994, 300:281-290.
• [48]Müller-Newen G: The cytokine receptor gp130: faithfully promiscuous. Sci STKE 2003, 201:pe40.
• [49]März P, Otten U, Rose-John S: Neural activities of IL-6-type cytokines often depend on soluble cytokine receptors. Eur J Neurosci 1999, 11:2995-3004.
• [50]Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T: Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989, 58:573-581.
• [51]Fischer A, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, Grotzinger J, Rose-John S: A bioactive designer cytokine for human haematopoietic progenitor cell expansion. Nat Biotechnol 1997, 15:142-145.
• [52]Schäfer KH, Mestres P, März P, Rose-John S: The IL-6/sIL-6R fusion protein hyper-IL-6 promotes neurite outgrowth and neuron survival in cultured enteric neurons. J Interferon Cytokine Res 1999, 19:527-532.
• [53]Brazda V, Klusakova I, Svizenska I, Veselkova Z, Dubovy P: Bilateral changes in IL-6 protein but not its receptor fp130 in rat dorsal root ganglia following sciatic nerve ligature. Cell Mol Neurobiol 2009, 29:1053-1062.
• [54]Miao T, Wu D, Zhang Y, Bo X, Subang MC, Wang P, Richardson PM: Suppressor of cytokine signaling-3 suppresses the ability of activated signal transducer and activator of transcription-3 to stimulate neurite growth in rat primary sensory neurons. J Neurosci 2006, 26:9512-9519.
• [55]Wang L, Lee HK, Seo OA, Shin YK, Lee KY, Park HT: Cell type-specific STAT3 activation by gp130-relaed cytokines in the peripheral nerves. Neuroreport 2009, 20:663-668.
• [56]Nelson TE, Ur CL, Gruol DL: Chronic interleukin-6 exposure alters electrophysiological properties and calcium signaling in developing cerebellar purkinje neurons in culture. J Neurophysiol 2002, 88:475-486.
• [57]Moalem G, Grafe P, Tracey DJ: Chemical mediators enhance the excitability of unmyelinated sensory axons in normal and injured peripheral nerve of the rat. Neurosci 2005, 134:1399-1411.
• [58]Lumpkin Ea, Caterina MJ: Mechanisms of sensory transduction in the skin. Nature 2007, 445:858-865.
• [59]Christensen AP, Corey DP: TRP channels in mechanosensation: direct or indirect activation? Nat Rev Neurosci 2007, 8:510-521.
• [60]Kimball ES, Prouty SP, Pavlick KP, Wallace NH, Schneider CR, Hornby PJ: Stimulation of neuronal receptors, neuropeptides and cytokines during experimental oil of mustard colitis. Neurogastroenterol Motil 2007, 19:390-400.
• [61]Rabe B, Chalaris A, May U, Waetzig GH, Seegert D, Williams AS, Jones SA, Rose-John S, Scheller J: Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 2008, 111:1021-1028.
• [62]Melton L, Coombs A: Actemra poised to launch IL-6 inhibitors. Nat Biotechnol 2008, 26:957-959.
• [63]Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R, OPTION investigators: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987-997.
• [64]Dixon WJ: Efficient analysis of experimental observations. Ann Rev Pharmacol Toxicol 1980, 20:441-462.
• [65]Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Meth 1994, 53:55-63.
• [66]Reeh PW: Sensory receptors in mammalian skin in an in vitro preparation. Neurosci Lett 1986, 66:141-147.
• [67]Bretag A: Synthetic interstitial fluid for isolated mammalian tissue. Life Sci 1969, 8:319-329.
• [68]Bennett GJ, Xie YK: A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988, 33:87-107.
• [69]Schäfers M, Geis C, Svensson CI, Luo ZD, Sommer C: Selective increase of tumour necrosis factor-alpha in injured and spared myelinated primary afferents after chronic constrictive injury of rat sciatic nerve. Eur J Neurosci 2003, 17:791-804.